AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21505058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose epoetin-β (35 IU/kg body weight, subcutaneously once weekly for 6 months)
Number of subjects: 24
Study 21505058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose epoetin-β
Number of subjects: 24
Study 21505058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21505058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EPO and placebo)
Number of subjects: 24
Study 18261731 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 79
Study 18261731 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 79
Study 17056812 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid-rich soups and beverages
Number of subjects: 0
Study 17056812 — intervention group
Group type: COMPARATOR
Intervention: Control vegetable soups and beverages
Number of subjects: 0
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate preload (1 MJ)
Number of subjects: 20
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat preload (1 MJ)
Number of subjects: 20
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual meal frequency
Number of subjects: 20
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated meal frequency
Number of subjects: 20
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient composition
Number of subjects: 20
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose declines
Number of subjects: 20
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetness perception and hunger suppression
Number of subjects: 20
Study 11791154 — intervention group
Group type: EXPERIMENTAL
Intervention: Average baseline blood glucose levels
Number of subjects: 20
Study 10470699 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD
Number of subjects: 78
Study 10470699 — intervention group
Group type: COMPARATOR
Intervention: Medical management (controls)
Number of subjects: 78
Study 7484039 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 2 mg.kg‐1
Number of subjects: 59
Study 7484039 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 3 mg.kg‐1
Number of subjects: 59
Study 7484039 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 0.03 mg.kg‐1
Number of subjects: 59
Study 7484039 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 59
Study 2150022 — intervention group
Group type: EXPERIMENTAL
Intervention: 840 mg stepronin, twice daily for 30 days
Number of subjects: 15
Study 2150022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6252641 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (Premarin) and medrogestone (Colpro)
Number of subjects: 23
Study 6252641 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (Dixarit)
Number of subjects: 23
Study 6131760 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 34
Study 6131760 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 34
Study 6131760 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and Metoprolol
Number of subjects: 34
Study 29578647 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR (Ranbaxy Laboratories Limited)
Number of subjects: 48
Study 29578647 — intervention group
Group type: COMPARATOR
Intervention: Diamicron MR (Servier)
Number of subjects: 48
Study 29970156 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview administration of PROM
Number of subjects: 808
Study 29970156 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaire administration of PROM
Number of subjects: 808
Study 29970156 — intervention group
Group type: EXPERIMENTAL
Intervention: Online questionnaire administration of PROM
Number of subjects: 808
Study 29970156 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview administration of PROM
Number of subjects: 808
Study 27884360 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB) angioplasty
Number of subjects: 181
Study 27884360 — intervention group
Group type: COMPARATOR
Intervention: Standard Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 181
Study 25350119 — intervention group
Group type: EXPERIMENTAL
Intervention: rectally applied tenofovir 1% gel
Number of subjects: 18
Study 22992963 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone LMA-C
Number of subjects: 140
Study 22992963 — intervention group
Group type: COMPARATOR
Intervention: PVC-based extra glottic airway devices
Number of subjects: 140
Study 22992963 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 140
Study 22992963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra group
Number of subjects: 140
Study 21219785 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective ECG-triggered spiral scan
Number of subjects: 60
Study 21219785 — intervention group
Group type: COMPARATOR
Intervention: Prospective ECG-triggered sequential scan
Number of subjects: 60
Study 18808621 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-mind-spirit group therapy (10 sessions, 180 minutes each)
Number of subjects: 28
Study 18808621 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 28
Study 16160590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg
Number of subjects: 112
Study 16160590 — intervention group
Group type: COMPARATOR
Intervention: General measures (Control)
Number of subjects: 112
Study 11801708 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr plus 50 mg/m(2) cisplatin
Number of subjects: 70
Study 11801708 — intervention group
Group type: COMPARATOR
Intervention: 89Sr plus placebo
Number of subjects: 70
Study 10395624 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (18 g/d)
Number of subjects: 21
Study 10395624 — intervention group
Group type: COMPARATOR
Intervention: Control (similar foods without inulin)
Number of subjects: 21
Study 8788865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentally simulated actions in a virtual reality environment
Number of subjects: 15
Study 1968126 — intervention group
Group type: EXPERIMENTAL
Intervention: New bedding constructed with a vapour‐permeable waterproof fabric that is impermeable to house dust mite antigen (Der p1).
Number of subjects: 0
Study 1968126 — intervention group
Group type: COMPARATOR
Intervention: Control samples from mattresses cleaned conventionally.
Number of subjects: 0
Study 6987291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed pollen extract (0.53 ml of 1:312,500 w/v, mean cumulative dose of 0.094 micrograms of ragweed AgE)
Number of subjects: 24
Study 6987291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered by the Rinkel method)
Number of subjects: 24
Study 6987291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed pollen extract
Number of subjects: 24
Study 6987291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31525083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut BP-SES (60 μm)
Number of subjects: 1234
Study 31525083 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut DP-EES (81 μm)
Number of subjects: 1234
Study 29166182 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) education
Number of subjects: 26
Study 29166182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no KMC education)
Number of subjects: 26
Study 26440516 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D (1g calcium/400IU vitamin D daily)
Number of subjects: 36282
Study 26440516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 26440516 — intervention group
Group type: COMPARATOR
Intervention: WHI Observational Study (WHI OS)
Number of subjects: 36282
Study 23999278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 238
Study 21505367 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based follow-up care plus cereal-based supplementary food (C-SF)
Number of subjects: 507
Study 21505367 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based follow-up care plus psychosocial stimulation (C-PS)
Number of subjects: 507
Study 21505367 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based follow-up care plus both cereal-based supplementary food and psychosocial stimulation (C-SF + PS)
Number of subjects: 507
Study 21505367 — intervention group
Group type: COMPARATOR
Intervention: Community-based follow-up care (C-C)
Number of subjects: 507
Study 21505367 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based follow-up care (H-C)
Number of subjects: 507
Study 21505367 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based follow-up care with supplementary food (SF)
Number of subjects: 507
Study 21505367 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based follow-up care
Number of subjects: 507
Study 20439550 — intervention group
Group type: COMPARATOR
Intervention: Navy beans canned in Canada or UK, homemade navy beans, 300 ml glucose drink (50 g available carbohydrate)
Number of subjects: 43
Study 20439550 — intervention group
Group type: COMPARATOR
Intervention: Canned navy beans in tomato sauce, maple style, with pork and molasses, homemade navy beans with pork and molasses
Number of subjects: 43
Study 20439550 — intervention group
Group type: COMPARATOR
Intervention: 4 equicaloric (300-kcal) treatments of pulses
Number of subjects: 43
Study 20439550 — intervention group
Group type: EXPERIMENTAL
Intervention: Navy beans
Number of subjects: 43
Study 20439550 — intervention group
Group type: COMPARATOR
Intervention: White bread
Number of subjects: 43
Study 20439550 — intervention group
Group type: COMPARATOR
Intervention: Glucose drink, white bread
Number of subjects: 43
Study 17516492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) for 15 days, 30 min daily at 7,500 lux
Number of subjects: 36
Study 17516492 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 15 days, 30 min daily at 950 lux
Number of subjects: 36
Study 15248924 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha plus THP
Number of subjects: 68
Study 15248924 — intervention group
Group type: COMPARATOR
Intervention: THP
Number of subjects: 68
Study 11887944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iopromide)
Number of subjects: 126
Study 11887944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 11887944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast medium (diatrizoate sodium)
Number of subjects: 126
Study 10193543 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thermodilution (CCO) using Vigilance software version 4.35 and 4.39
Number of subjects: 56
Study 10193543 — intervention group
Group type: COMPARATOR
Intervention: Iced bolus thermodilution (BCO)
Number of subjects: 56
Study 10193543 — intervention group
Group type: COMPARATOR
Intervention: Room temperature bolus thermodilution (BCO)
Number of subjects: 56
Study 7763199 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (50-60 U/kg)
Number of subjects: 9
Study 7763199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 9
Study 2184488 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (flurazepam 15 or 30 mg, triazolam 0.25 or 0.50 mg) and caffeine (250 mg)
Number of subjects: 80
Study 2184488 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 80
Study 2184488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both benzodiazepines and caffeine)
Number of subjects: 80
Study 7028356 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin (TMZ)
Number of subjects: 26
Study 7028356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 26
Study 30195561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacidified liquid human milk fortifier
Number of subjects: 164
Study 30195561 — intervention group
Group type: COMPARATOR
Intervention: Acidified liquid human milk fortifier
Number of subjects: 164
Study 25452222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 46
Study 25452222 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 46
Study 25452222 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy and Guided mastery therapy
Number of subjects: 46
Study 25105367 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 vaccine
Number of subjects: 0
Study 22299661 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal magnesium dialysate (1.8 mg/dL)
Number of subjects: 22
Study 22299661 — intervention group
Group type: EXPERIMENTAL
Intervention: Low magnesium dialysate (0.6 mg/dL)
Number of subjects: 22
Study 22299661 — intervention group
Group type: COMPARATOR
Intervention: Both groups (normal and low magnesium)
Number of subjects: 22
Study 20584515 — intervention group
Group type: EXPERIMENTAL
Intervention: PREG-30 (30 mg/d)
Number of subjects: 58
Study 20584515 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (400 mg/d)
Number of subjects: 58
Study 20584515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20584515 — intervention group
Group type: EXPERIMENTAL
Intervention: PREG-200 (200 mg/d)
Number of subjects: 58
Study 17921407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil consumption with Thr54 variant
Number of subjects: 1226
Study 17921407 — intervention group
Group type: COMPARATOR
Intervention: Olive oil consumption
Number of subjects: 1226
Study 17921407 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between Ala54Thr polymorphism and type of oil consumed
Number of subjects: 1226
Study 16350601 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 183
Study 16350601 — intervention group
Group type: COMPARATOR
Intervention: atomoxetine
Number of subjects: 183
Study 11986479 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE + PT
Number of subjects: 81
Study 11986479 — intervention group
Group type: COMPARATOR
Intervention: LSE-alone
Number of subjects: 81
Study 9704715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 710
Study 9704715 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 710
Study 8045968 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily biosynthetic GH (25 U/m2.week)
Number of subjects: 44
Study 8045968 — intervention group
Group type: COMPARATOR
Intervention: Twice daily biosynthetic GH (25 U/m2.week)
Number of subjects: 44
Study 8045968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 2928987 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow sodium (80 mmol/day)
Number of subjects: 36
Study 2928987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2928987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 36
Study 31380297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 28592706 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide 20mg, 40mg, or 60mg
Number of subjects: 33
Study 26144968 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (serotonin reuptake inhibitor)
Number of subjects: 0
Study 26144968 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (dopamine precursor)
Number of subjects: 0
Study 26144968 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 26144968 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 26144968 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and Levodopa
Number of subjects: 0
Study 22940056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of influenza vaccine
Number of subjects: 65
Study 22940056 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of influenza vaccine
Number of subjects: 65
Study 22940056 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination ≥ 1 year post-transplantation
Number of subjects: 65
Study 22940056 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood (UCB) recipients
Number of subjects: 65
Study 22940056 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of CD19(+) cells before vaccination
Number of subjects: 65
Study 21943315 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry-based culturally sensitive collaborative treatment (T-CSCT)
Number of subjects: 0
Study 21943315 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 18495695 — intervention group
Group type: EXPERIMENTAL
Intervention: ehCG (5000 IU)
Number of subjects: 0
Study 18495695 — intervention group
Group type: EXPERIMENTAL
Intervention: rhCG (250 microg / 6500 IU)
Number of subjects: 0
Study 18495695 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH (150 IU)
Number of subjects: 0
Study 18495695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18495695 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH
Number of subjects: 0
Study 17047615 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin
Number of subjects: 50
Study 17047615 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 50
Study 17047615 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of atorvastatin
Number of subjects: 50
Study 12714021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg every 12h for 4-7 days)
Number of subjects: 439
Study 10722441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (iv) ceftriaxone
Number of subjects: 30
Study 10722441 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 30
Study 8762788 — intervention group
Group type: EXPERIMENTAL
Intervention: One distal locking screw
Number of subjects: 44
Study 8762788 — intervention group
Group type: COMPARATOR
Intervention: Two distal locking screws
Number of subjects: 44
Study 8762788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 8497018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warm-up (LWU) - 366-m swim at 70% VO2 max
Number of subjects: 10
Study 8497018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity warm-up (HWU) - four 46-m swims at 1-min intervals at 110% VO2 max
Number of subjects: 10
Study 8497018 — intervention group
Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 10
Study 3578255 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (n = 53)
Number of subjects: 100
Study 3578255 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy (Control group)
Number of subjects: 100
Study 31938843 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of pediatric appropriate use criteria (AUC)
Number of subjects: 1079
Study 31938843 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator chart review
Number of subjects: 1079
Study 31938843 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE findings in 'rarely appropriate' encounters
Number of subjects: 1079
Study 29402628 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with propofol
Number of subjects: 40
Study 29402628 — intervention group
Group type: COMPARATOR
Intervention: Volatile Induction and Maintenance of Anesthesia (VIMA) with sevoflurane
Number of subjects: 40
Study 27692113 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft plus BMP-7 (OP-1)
Number of subjects: 110
Study 27692113 — intervention group
Group type: COMPARATOR
Intervention: Allograft alone
Number of subjects: 110
Study 25730415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion/alcohol
Number of subjects: 179
Study 25730415 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan depletion/placebo
Number of subjects: 179
Study 25730415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-balanced control/alcohol
Number of subjects: 179
Study 25730415 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced control/placebo
Number of subjects: 179
Study 23735474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT)
Number of subjects: 80
Study 23735474 — intervention group
Group type: COMPARATOR
Intervention: Manual thrombus aspiration (MTA)
Number of subjects: 80
Study 21286008 — intervention group
Group type: EXPERIMENTAL
Intervention: GC501 trivalent inactivated influenza vaccine
Number of subjects: 329
Study 19394473 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption (25 to 168 g/day)
Number of subjects: 142
Study 16567606 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/d)
Number of subjects: 1252
Study 16567606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1252
Study 12756353 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic venous disease severity assessed by visual inspection (categories: normal, telangiectasias and spider veins, varicose veins, trophic changes)
Number of subjects: 2404
Study 12756353 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic venous disease severity assessed by duplex ultrasound (categories: normal, superficial venous disease, deep vein disease)
Number of subjects: 2404
Study 12756353 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional scales of the SF-36
Number of subjects: 2404
Study 12756353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health scales of the SF-36
Number of subjects: 2404
Study 11426633 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus INF (5Mu INF s.c. for 5 days on days 22 to 26 of each 28 day cycle, followed by INF 5 million units thrice weekly for 52 weeks for responders)
Number of subjects: 435
Study 11426633 — intervention group
Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 435
Study 11426633 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus INF
Number of subjects: 435
Study 9335522 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere) - 3 cycles as neoadjuvant treatment
Number of subjects: 292